Skip to main content
. 2011 Oct 20;16(11):1508–1519. doi: 10.1634/theoncologist.2011-0115

Figure 1.

Figure 1.

Differentiation of HFSR and HFS [26, 27, 33, 53, 58, 59, 69].

Abbreviations: HFS, hand–foot syndrome; HFSR, hand–foot skin reaction; IP, interphalangeal.

Modified with permission from (i) Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003;26:435–436, with permission. (ii) Photographs reprinted from Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886–892 (multikinase inhibitors). Copyright © 2008 American Medical Association. All rights reserved. (iii) Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(suppl 1):S31–S40 (anthracyclines/antimetabolites), with permission, and photograph courtesy of Mario Lacouture, M.D. (taxane).